The sBLA is supported by results from the pivotal phase 3 TROPION-Breast02 clinical trial (NCT05374512), which evaluated the ...
The FDA accepted a supplemental biologics license application and granted priority review for Datroway for adults ...
By targeting proteins used to splice genes, UC San Diego researchers have unlocked a new approach to treating triple-negative ...
DATROWAY Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic TNBC Who Are Not Candidates ...
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...
A new experimental vaccine could slow down triple negative breast cancer and reduce its recurrence after treatment.
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment ...
Verywell Health on MSN
What you need to know about triple-negative breast cancer with chemo resistance
Medically reviewed by Marla Anderson, MD Key Takeaways Triple-negative breast cancer is aggressive and often resists ...
Significantly longer progression-free survival seen among patients with previously untreated, PD-L1 advanced or metastatic ...
Antal and Yeo, who also are members of UCSD’s Moores Cancer Center, say the key to targeting triple-negative breast cancer, or TNBC, is managing a protein called poly (U)-binding splicing factor 60, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results